Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > GeneSegues Announces Allowance in Europe of New Patent Broadly Covering Targeted Drug Delivery At Sub-50 Nanometer Scale: Notification of “Intent to Grant” for Nanocapsule Composition and Methods

Abstract:
GeneSegues, Inc., a leader in drug delivery at the sub-50 nanometer scale, announced today that the European Patent Office (EPO) has issued a notification of intent to grant for a patent covering the company's proprietary drug delivery technology (EP Application No. 01920161.5). This patent stems from pioneering work by the company in delivering therapeutic molecules such as oligonucleotides and plasmid DNA to target cells using nanocapsules of less than 50 nanometers in diameter. Compositions of this size impart significant advantages including entering the target cell without triggering defense mechanisms that can degrade the capsule and drug.

GeneSegues Announces Allowance in Europe of New Patent Broadly Covering Targeted Drug Delivery At Sub-50 Nanometer Scale: Notification of “Intent to Grant” for Nanocapsule Composition and Methods

Minneapolis, MN | Posted on March 6th, 2012

"We are gratified that the EPO has recognized the importance and patentability of our discoveries in nonviral technologies that can take advantage of efficient lipid raft pathways into the target cell," said Gretchen Unger, Ph.D., Chief Scientific Officer and founder of GeneSegues. "This patent covers a broad and significant technology platform which we are continuing to develop with collaborators across a range of applications including cancer, liver, and infectious diseases."

The new patent includes claims covering compositions of sub-50 nanometer capsules and methods of formulation. The composition claims cover sub-50 nanometer capsules that consist of a substitutable biopolymer ligand shell which can actively target the composition to any desired cell type, and can encapsulate large or small molecule drug cargo. The method claims cover the processes for formulating the nanocapsules with a novel design that is both versatile and scalable.

####

About GeneSegues, Inc.
GeneSegues is a biopharmaceutical company focused on applying its novel drug delivery technology to produce breakthrough nucleic acid-based therapeutics and vaccines for the treatment and prevention of serious diseases. The company’s sub-50 nanometer (‘s50’) capsule technology addresses the series of biological barriers that prevent nucleic acids from reaching the therapeutically-important cytoplasm and nucleus of the target cell.

For more information, please click here

Contacts:
Gretchen Unger, Ph.D.
Chief Scientific Officer
GeneSegues, Inc.
952.443.3798

Copyright © GeneSegues, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Haydale Secures Exclusive Development and Supply Agreement with Tantec A/S: New reactors to be built and commissioned by Tantec A/S represent another step forward towards the commercialisation of graphene October 24th, 2014

QuantumWise guides the semiconductor industry towards the atomic scale October 24th, 2014

MEMS & Sensors Technology Showcase: Finalists Announced for MEMS Executive Congress US 2014 October 23rd, 2014

Nanoparticle technology triples the production of biogas October 23rd, 2014

Nanomedicine

NYU Researchers Break Nano Barrier to Engineer the First Protein Microfiber October 23rd, 2014

Iranian Scientists Apply Nanotechnology to Produce Surgery Suture October 23rd, 2014

RF Heating of Magnetic Nanoparticles Improves the Thawing of Cryopreserved Biomaterials October 23rd, 2014

Sopping up proteins with thermosponges: Researchers develop novel nanoparticle platform that proves effective in delivering protein-based drugs October 22nd, 2014

Announcements

Haydale Secures Exclusive Development and Supply Agreement with Tantec A/S: New reactors to be built and commissioned by Tantec A/S represent another step forward towards the commercialisation of graphene October 24th, 2014

QuantumWise guides the semiconductor industry towards the atomic scale October 24th, 2014

Advancing thin film research with nanostructured AZO: Innovnano’s unique and cost-effective AZO sputtering targets for the production of transparent conducting oxides October 23rd, 2014

Strengthening thin-film bonds with ultrafast data collection October 23rd, 2014

Patents/IP/Tech Transfer/Licensing

Researchers patent a nanofluid that improves heat conductivity October 22nd, 2014

Nanodevices for clinical diagnostic with potential for the international market: The development is based on optical principles and provides precision and allows saving vital time for the patient October 15th, 2014

Aculon Receives Patent for Application of Enhanced Bonding Layers on Titanium October 9th, 2014

harmaEngine will join Nanobiotix’ pivotal trial for NBTXR3 in Soft Tissue Sarcoma to accelerate its development in Asia-Pacific: PharmaEngine to make milestone payment to Nanobiotix in October 2014 to recognize the value created October 8th, 2014

NanoNews-Digest
The latest news from around the world, FREE





  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE